Article

GALILEO: Aflibercept provides marked improvement in visual acuity in results from follow-up to 76 weeks

Intravitreal injection of aflibercept provides marked improvement in visual acuity in treatment-naive eyes with macular edema secondary to central retinal vein occlusion in results from follow-up to 76 weeks in the phase III GALILEO study.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
Related Content
Alcon agrees to purchase LENSAR
March 25th 2025

Alcon agrees to purchase LENSAR

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

ZEISS VISULAS Combi availability expands to Canada
March 24th 2025

ZEISS VISULAS Combi availability expands to Canada

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial
March 24th 2025

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial

Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis
March 24th 2025

Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis

© 2025 MJH Life Sciences

All rights reserved.